Pliant Therapeutics(PLRX) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results BEACON-IPF Phase 2b trial on track for full enrollment in the first quarter of 2025 with data anticipated in mid-2026 SOUTH SAN FRANCISCO, CA., November 7, 2024 - Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage clinical biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today provided a corporate update and reported th ...